Group 2 innate lymphoid cells boost CD8+ T-cell activation in anti-tumor immune responses

Group 2 innate lymphoid cells (ILC2s) are essential for orchestrating type 2 immune responses during allergic airway inflammation and infection. ILC2s have been reported to play a regulatory role in tumors; however, this conclusion is controversial. In this study, we showed that IL-33-activated ILC2...

Full description

Saved in:
Bibliographic Details
Published in:Oncoimmunology 2023-12, Vol.12 (1), p.2243112-2243112
Main Authors: Wen, Jing, Cheng, Shipeng, Wang, Ran, Huang, Yuying, Xu, Long, Ma, Liyan, Ling, Zhiyang, Xu, Jinfu, Zhao, Deping, Zhang, Yaguang, Sun, Bing
Format: Article
Language:English
Subjects:
anti-tumor response
antigen presentation
CD8 T cell
ILC2
Original Research
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Group 2 innate lymphoid cells (ILC2s) are essential for orchestrating type 2 immune responses during allergic airway inflammation and infection. ILC2s have been reported to play a regulatory role in tumors; however, this conclusion is controversial. In this study, we showed that IL-33-activated ILC2s could boost CD8 + T-cell function through direct antigen cross-presentation. After activation by IL-33, ILC2s showed an enhanced potential to process antigens and prime CD8 + T cell activation. Activated ILC2s could phagocytose exogenous antigens in vivo and in vitro, promoting antigen-specific CD8 + T cell function to enhance antitumor immune responses. Administration of OVA-loaded ILC2s induces robust antitumor effects on the OVA-expressing tumor model. These findings suggested that the administration of tumor antigen-loaded ILC2s might serve as a potential strategy for cancer treatment.
ISSN:2162-402X
2162-4011
2162-402X
DOI:10.1080/2162402X.2023.2243112